Supplementary Table S1.
Detailed Demographic Characteristics of Patients with MF/SS (n = 45) and Healthy Controls (n = 20)
| Gender | Age (y) | Race/Ethnicity | Diagnosis | Stage | mSWAT | Comorbidities | Skin-Directed Therapy | Systemic Therapy |
|---|---|---|---|---|---|---|---|---|
| Healthy controls (n = 20) | ||||||||
| F | 34 | Asian | — | — | — | None | — | — |
| M | 25 | Asian | — | — | — | None | — | — |
| M | 26 | White | — | — | — | None | — | — |
| M | 37 | White | — | — | — | None | — | — |
| M | 24 | Asian | — | — | — | None | — | — |
| F | 27 | White/Hispanic | — | — | — | None | — | — |
| F | 60 | White | — | — | — | GERD, DLP, hypothyroidism, migraines, rheumatoid arthritis | — | — |
| F | 68 | White | — | — | — | DLP | — | — |
| M | 76 | White | — | — | — | GERD, DLP, HTN, T2DM | — | — |
| F | 74 | White | — | — | — | Asthma, CM, CKD (stage III), GERD, DLP, HTN, hypothyroidism, T2DM | — | — |
| F | 54 | White | — | — | — | None | — | — |
| M | 55 | White | — | — | — | None | — | — |
| F | 65 | White | — | — | — | GERD, DLP, T2DM | — | — |
| F | 74 | White | — | — | — | GERD, DLP, HTN | — | — |
| M | 38 | Other/Hispanic | — | — | — | GERD, HTN | — | — |
| M | 79 | White | — | — | — | HTN | — | — |
| F | 54 | White | — | — | — | None | — | — |
| F | 58 | White | — | — | — | DLP, HTN, hypothyroidism, T2DM | — | — |
| M | 66 | White | — | — | — | None | — | — |
| M | 47 | White | — | — | — | None | — | — |
| Patient with MF/SS (n = 45) | ||||||||
| M | 71 | White | FMF | IIIB | 35 | Bladder cancer, GERD, DLP, T2DM |
TCS | Acitretin |
| M | 65 | White | FMF | IIIA | 90 | GERD | TCS | — |
| F | 18 | White/Hispanic | FMF | IB | 26 | Asthma, GERD | TCS, NBUVB | IFN-α-2b |
| M | 56 | White/Hispanic | FMF | IB | 16 | Anemia, CKD, GERD, glaucoma, DLP, HTN, T2DM, vertebral osteomyelitis | TCS, TCI, NBUVB | — |
| F | 72 | White | FMF | IB | 5 | Diverticulitis, GERD, DLP, hypothyroidism, infiltrating ductal carcinoma | TCS | IFN-α-2b, bexarotene |
| M | 36 | White/Hispanic | FMF | IB | 3 | DLP, T2DM | TCS | — |
| F | 74 | White | FMF | IIB | 18 | DLP, HTN | TCS, TCI | Acitretin |
| F | 35 | Other/Hispanic | FMF | IB | 28 | None | — | — |
| F | 63 | Black | FMF | IIB | 13 | DLP, HTN, hypothyroidism, obesity | TCS, NBUVB | — |
| M | 67 | White | FMF/SMF | IB | 13 | DLP, HTN | TCS, NBUVB, XRT | IFN-α-2b, acitretin |
| M | 55 | White | FMF/SMF | IB | 3 | None | TCS, NBUVB | — |
| M | 69 | White | CD4+ MF | IIB | 7 | CAD, insomnia, obesity, overactive bladder | TCS | — |
| M | 49 | Asian | CD4+ MF | IB | 60 | Cataracts, ED, mitral regurgitation, obesity, T2DM | — | — |
| M | 37 | White/Hispanic | CD4+ MF | IIB | 65 | None | TCS, NBUVB | IFN-α-2b |
| M | 47 | White | CD4+ MF | IB | 4 | GERD, obesity | TCS | — |
| M | 58 | White | CD4+ MF | IIA | 22 | Autoimmune hemolytic anemia, anaplastic large cell lymphoma, asthma, HTN, hyperthyroidism, obesity, OSA | TCS | Acitretin |
| M | 65 | White | CD4+ MF | IA | 13 | GERD, HTN, DLP, OSA, T2DM | TCS | — |
| F | 37 | White/Hispanic | CD4+ MF | IB | 25 | HTN, hypothyroidism, OSA | TCS, NBUVB | Bexarotene, acitretin |
| F | 72 | Black | CD4+ MF | IIIA | 100 | DLP, HTN, T2DM | TCS | — |
| M | 69 | White | CD4+ MF | IIIA | 14 | AF, BPH, CAD, DLP, T2DM | TCS | — |
| M | 67 | White | CD4+ MF | IIB | 4.5 | CRC, DLP | TCS, Imiquimod | Acitretin |
| M | 52 | White | CD4+ MF | IB | 13 | Allergic rhinitis | TCS | — |
| M | 81 | White | CD4+ MF | IB | 10 | BPH, DLP, PAF, prostate cancer | TCS | Bexarotene |
| F | 74 | White | CD4+ MF | IA | 5 | Hypothyroidism | TCS | — |
| M | 65 | White | CD4+ MF | IA | 5 | DLP, GERD, HTN, obesity, T2DM | TCS | — |
| M | 61 | White | CD4+ MF | IA | 6 | HTN | TCS | — |
| F | 26 | White | CD4+ MF | IB | 68 | Migraine | — | — |
| M | 63 | White | CD4+ MF | IIB | 6 | Hypothyroidism | TCS | — |
| F | 72 | Black | CD4+ MF | IIIA | 85 | Glaucoma, DLP, HTN | TCS | — |
| F | 61 | White | CD4+ MF | IA | 2 | GERD, endometriosis, osteoporosis, primary hyperparathyroidism | — | — |
| M | 74 | White | CD4+ MF | IA | 22 | Osteoarthritis, BPH, CKD, GERD, glaucoma, HTN, ulnar neuropathy | TCS | Methotrexate, bexarotene |
| M | 46 | Black | CD4+ MF | IIB | 60 | Asthma, bronchitis | TCS | — |
| M | 62 | White | CD4+ MF | IB | 23 | DLP | — | — |
| F | 55 | White | CD4+ MF | IB | 25 | Asthma, COPD, GERD, DLP, HTN, PAD, PFO | — | — |
| M | 68 | White | CD4+ MF | IIB | 50 | DLP, HTN | — | — |
| M | 55 | White | CD4+ MF | IB | 10 | DLP, HTN, obesity | — | — |
| M | 72 | White | CD4+ MF | IIIB | 95 | Atrial flutter, anxiety, cervical stenosis, CKD, ED, DLP, HTN, lumbar disc herniation, OSA, PAF, prostate cancer, tachycardia-induced CM | TCS | Brentuximab vedotin |
| F | 58 | Asian | CD4+ MF | IB | 14 | Breast cancer, DLP, HTN, multinodular goiter, T2DM | TCS | — |
| M | 29 | White/Hispanic | CD8+ MF | IB | 24 | None | TCS | — |
| F | 46 | White | CD8+ MF | IA | 15 | Allergic rhinitis, fibroids, obesity | — | — |
| M | 66 | White | SS | IV | 10 | AF, dysphagia, DLBCL, DLP, HSV keratitis, hypothyroidism | TCS | — |
| F | 56 | White | SS | IV | 24 | DLP, HTN, hypothyroidism | TCS | — |
| M | 83 | White | SS | IV | 100 | CAD, HTN | TCS | Methotrexate |
| F | 66 | White | SS | IV | 28 | DLP, hypothyroidism | TCS | — |
| M | 67 | Black | SS | IV | 32 | Atrial flutter, CAD, ED, HFrEF, DLP, HTN, obesity, T2DM | TCS | — |
Abbreviations: AF, atrial fibrillation; BPH, benign prostatic hyperplasia; CAD, coronary artery disease; CM, cardiomyopathy; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRC, colorectal carcinoma; DLBCL, diffuse large B-cell lymphoma; DLP, dyslipidemia; ED, erectile dysfunction; F, female; FMF, folliculotropic mycosis fungoides; GERD, gastroesophageal reflux disease; HFrEF, heart failure with reduced ejection fraction; HSV, herpes simplex virus; HTN, hypertension; LCT, large cell transformation; M, male; MF, mycosis fungoides; mSWAT, modified Severity Weighted Assessment Tool; NBUVB, narrowband UVB; OSA, obstructive sleep apnea; PAD, peripheral artery disease; PAF, paroxysmal atrial fibrillation; PFO, patent foramen ovale; SMF, syringotropic mycosis fungoides; SS, Sézary syndrome; T2DM, type 2 diabetes mellitus; TCI, topical calcineurin inhibitor; TCS, topical corticosteroids; XRT, localized radiotherapy.